ETON - Eton Pharmaceuticals, Inc.
IEX Last Trade
12.98
0.010 0.077%
Share volume: 2,470
Last Updated: Fri 27 Dec 2024 08:30:26 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$12.97
0.01
0.08%
Fundamental analysis
22%
Profitability
8%
Dept financing
28%
Liquidity
75%
Performance
22%
Performance
5 Days
8.56%
1 Month
6.51%
3 Months
133.97%
6 Months
308.73%
1 Year
191.83%
2 Year
352.33%
Key data
Stock price
$12.98
DAY RANGE
$12.80 - $13.68
52 WEEK RANGE
$3.20 - $13.98
52 WEEK CHANGE
$209.82
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Sean E. Brynjelsen
Region: US
Website: etonpharma.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: etonpharma.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Eton Pharmaceuticals, Inc. focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting from vasodilation in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age.
Recent news